[ad_1]
The CDK4 / 6 Inhibitor Improves Overall Survival in Accuracy on Precision Oncology Prenopausal Breast Cancer Precancer Subgroup
The results of a phase III trial presented at ASCO suggest a significant increase in overall survival by adding ribociclib to endocrine therapy …
View full coverage on Google News
[ad_2]
Source link
